DOCSLIB.ORG

4. April 2021 Sanctions List Full

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

GLOBAL LIST OF INELIGIBLE PERSONS* UPLOADED 29.04.2021 Period of Date of Date of Ineligibility Lifetime Infraction Name Nationality Role Sex Discipline 1 Discipline 2 Sanction Disqualification ADRV Rules ADRV Notes Description Birth Infraction until Ban? Type of results Long Distance In competition test, 2017 Baoneng Guangzhou Huangpu ABDOSH, Ali 25/08/1987 ETH athlete M 24/12/2017 4 years ineligibility 04/02/2022 Since 24-12-2017 No Doping Presence,Use Salbutamol (3000m+) Marathon , Guangzhou, CHN ABDUL SHAHID (NASERA), Haidar 13/01/1981 IRQ athlete M Throws 08/03/2019 4 years ineligibility 05/05/2023 Since 08.03.19 No Doping Presence,Use Metandienone In competition test, Iraqi Championships, Baghdad, IRQ Use or Attempted Use by an Athlete of a Use of a prohibited substance Middle Distance ACHERKI, Mounir 09/02/1981 FRA athlete M 1500m 01/01/2014 4 years ineligibility 15/04/2021 Since 01-01-2014 No Doping Use,Possession Prohibited Substance or a Prohibited Method, (800m-1500m) Possession of a Prohibited Substance or a Possession of a prohibited substance ADAMCHUK, Mariya 29/05/2000 UKR athlete F Long Jump Jumps 03/06/2018 4 years ineligibility 16/08/2022 Since 03.06.18 No Doping Presence,Use Trenbolone, DMBA & Methylhexaneamine ICT, Ukrainian club U20 Championships, Lutsk, UKR Sprints (400m or ADEKOYA, Kemi 16/01/1993 BRN athlete F 400m Hurdles 24/08/2018 4 years ineligibility 25/11/2022 Since 24.08.18 No Doping Presence,Use Stanozolol Out-of-competition test, Jakarta, IDN less) Sprints (400m or 8 years ineligibility (2nd In competition test, Warri Relays - CAA Super Grand Prix , ADELOYE, Tosin 07/02/1996 NGR athlete F 400m 24/07/2015 23/07/2023 Since 24-07-2015 No Doping Presence,Use Exogenous Steroids less) ADRV) Warri, NGR Sprints (400m or In competition test, 96th Malaysian Athletics ADLI SAIFUL, Muh. Syazrul 17/02/2001 MAS athlete M 18/08/2019 4 years ineligibility 12/12/2023 Since 18.08.19 No Doping Presence,Use Methasterone & Oxymetholone less) Championship 2019, Kuala Lumpur, MAS Long Distance ICT, Hungary 50km ultra running Championships 2019, ADOK, Roland 29/10/1984 HUN athlete M 01/05/2019 2 years ineligibility 22/05/2021 Since 01.05.19 No Doping Presence,Use Clenbuterol (3000m+) Budakalasz, HUN From 15.07.12 - (Retesting) In competition test, XXX Olympic Games, AGAFONOVA KHANAFEYEVA, Gulfiya RUS athlete F Hammer Throws 8 years ineligibility 05/01/2025 No Doping Presence,Use Dehydrochlormethyltestosterone; Use 06.08.14 London, GBR; McLaren evidence Long Distance AHMED, Belal 20/11/1986 EGY athlete M 27/09/2019 4 years ineligibility 03/12/2023 Since 27.09.19 No Doping Presence,Use EPO Out-of-competition test, Berlin, GER (3000m+) Sprints (400m or AHYE, Michelle-Lee 10/04/1992 TTO athlete F 19/04/2019 2 years ineligibility 18/04/2021 Since 19.04.19 No Doping Whereabouts Failures 3 Whereabouts Failures within 12 months 3 Whereabouts Failures within 12 months less) In competition test, Kingdom 1st Class Championships AL KHALIFA, Abdullah (Hussain) 16/01/1994 KSA athlete M Triple Jump Jumps 04/03/2017 4 years ineligibility 03/04/2021 Since 4.3.17 No Doping Presence,Use Stanozolol Jeddah, KSA Sprints (400m or AL-HASAN, Mohammad Yaseen 30/08/1993 KSA athlete M 400m 05/02/2016 4 years ineligibility 16/09/2021 Since 05-02-2016 No Doping Presence,Use Oxandrolone In competition test, Federation Cup, Qatif, KSA less) AL-MEQBALI, Rashed Saif 24/08/1978 UAE athlete M Shot Put Throws 31/05/2014 8 years ineligibility 30/05/2022 Since 31-05-2014 No Doping Presence,Use Stanozolol Out of competition test, Dubai, UAE Middle Distance In competition test, Russian Championships, Cheboksary, ALEKSANDROV, Maksim 27/03/1994 RUS athlete M 27/07/2019 4 years ineligibulity 13/08/2023 Since 27.07.19 No Doping Presence, Use EPO (800m-1500m) RUS Long Distance In competition test, Kazakhstan Junior Championships , ALIKULOV, Toshali 12/07/1999 KAZ athlete M 05/05/2018 4 years ineligibility 11/06/2022 Since 05-05-2018 No Doping Presence,Use Meldonium (3000m+) Shymkent, KAZ ALMSHDINY HAMID, Zenia 11/04/1988 IRQ athlete F Combined Events 07/03/2019 8 years ineligibility 29/07/2027 Since 07.03.19 No Doping Evasion,Refusal and or Failure to Submit Refusal In competition test, Iraqi Championships, Baghdad, IRQ Sprints (400m or In competition test, 'Asian Indoor Championships', Tehran ALSALEH, Monira 18/05/1985 SYR athlete F 200m 26/02/2010 Lifetime ban (2nd ADRV) Since 26-02-10 Yes Doping Presence,Use Stanozolol and Metenolone less) IRI Sprints (400m or From 08.08.12 to ANANENKO, Anis 29/11/1985 BLR athlete M 400m 08/08/2012 No Doping Presence,Use Dehydrochloromethyltestosterone In competition test, XXX Olympic Games, London, GBR less) 27.05.15 Long Distance ANDREAS, Jeromy 28/02/1992 RSA athlete M 08/09/2018 4 years ineligibility 29/10/2022 Since 08-09-2018 No Doping Presence,Use 1-Testosterone (3000m+) ANDREEV, Andrian 24/07/1977 BUL athlete M Hammer Throws 27/02/2008 Lifetime ban (2nd ADRV) Since 27-02-2008 Yes Doping Presence,Use Metenolone Out of competition test Long Distance In competition test, Maraton Internacional SESCPR , Foz ANTUNES, Luis Paolo 28/11/1980 BRA athlete M Race Walk 27/09/2015 8 years ineligibility 26/09/2023 Since 27.09.15 No Doping Presence,Use Stanozolol (3000m+) do Iguacu, BRA 3 years and 6 months Dehydrochloromethyltestosterone, Clomiphene, APHANE, Reneilwe 24/08/1990 RSA athlete M Triple Jump Jumps 31/01/2018 27/08/2021 Since 31.01.18 No Doping Presence,Use Out-of-competition test, Soshanguve, RSA ineligibility GW1516 Middle Distance ARZAMASOVA, Marina 17/12/1987 BLR athlete F 29/07/2019 4 years ineligibility 28/07/2023 Since 29.07.19 No Doping Presence, Use LGD-4033 (Ligandrol) Out-of-competition test, Yukhnovka, BLR (800m-1500m) Sprints (400m or In competition test, National indoor athletics ARZHANGNEZHAD, Ali 07/01/1999 IRI athlete M 11/01/2018 4 years ineligibility 12/03/2022 Since 11-01-2018 No Doping Presence,Use Stanozolol less) championships, Tehran, IRN www.athleticsintegrity.org 1 *updated till 29.04.2021 GLOBAL LIST OF INELIGIBLE PERSONS* UPLOADED 29.04.2021 Period of Date of Date of Ineligibility Lifetime Infraction Name Nationality Role Sex Discipline 1 Discipline 2 Sanction Disqualification ADRV Rules ADRV Notes Description Birth Infraction until Ban? Type of results Long Distance 8 years ineligibility (2nd In competition test, International Darica Half Marathon , ASLAN, Veysi 23/02/1984 TUR athlete M 09/10/2016 18/06/2025 From 09.10.16 No Doping Presence,Use EPO (3000m+) ADRV) Darica, TUR Long Distance On 26.10.14 and ASSILA, Anouar 01/01/1983 FRA athlete M 26/10/2014 4 years ineligibility 18/09/2021 No Doping Use Athlete Biological Passport Athlete Biological Passport Case (3000m+) 20.11.16 8 years ineligibility (2nd AVRAMENKO, Roman 23/03/1988 RUS athlete M Javelin Throws 30/07/2015 29/08/2023 Since 30.07.15 No Doping Presence,Use Dehydrochloromethyltestosterone Out-of competition test, Kirovske ADRV) In competition test, track & field 1st league final , Cankiri, Long Distance Since 29-08-2015 to 20- AYDEMIR, Mazlum 19/07/1983 TUR athlete M 29/08/2015 A life-time ineligibility Yes Doping Presence,Use Erythropoietin TUR & '60th Omer Besim Cross-Country Race' in Istanbul, (3000m+) 02-17 TUR Middle Distance AYHAN-KOP, Surreya 06/09/1978 TUR athlete F 1500m 08/09/2007 Lifetime ban (2nd ADRV) Since 08-09-07 Yes Doping Presence,Use Stanozolol Out of competition test (800m-1500m) Sprints (400m or AZIKE, Henry 07/01/1989 NGR athlete M 100m 05/12/2012 Lifetime ban (2nd ADRV) Since 05-12-12 Yes Doping Presence,Use Metenolone Out of competition test, Lagos, NGR less) Long Distance BAKER Sarkan 30/01/1983 IRQ athlete M 25/05/2018 4 years ineligibility 11/12/2022 Since 25-05-18 No Doping Presence,Use Meldonium Out of competition test, Baghdad, IRQ (3000m+) Long Distance BAKULIN, Sergey 13/11/1986 RUS athlete M Race Walk 20/05/2018 8 years ineligibility 02/04/2027 Since 20.05.18 No Doping Presence,Use Athlete Biological Passport Athlete Biological Passport Case (3000m+) Long Distance BALCIUNAITE, Zivile 03/04/1979 LTU athlete F Road Running 15/04/2016 8 years ineligibility 13/05/2024 Since 15.4.16 No Doping Presence,Use Meldonium Out of competition test, Palanga LTU (3000m+) Long Distance Presence,Use,Violation of the Prohibition of Ephedrine & EPO, Participation During BARBI, Roberto 25/03/1965 ITA athlete M Road Running 20/07/2008 38 years ineligibility 28/07/2047 Since 20.07.2008 No Doping In competition test, Mezza Maratona Mende, FRA (3000m+) Participation During Ineligibility Ineligibility 4 years and 2 months Clenbuterol, Exogenous Steroids after IRMS Long Distance Presence,Use,Violation of the Prohibition of In competition test, Granfondo Citta di Ancona, Ancona, BARCHI, Christian 04/03/1989 ITA athlete M 03/03/2019 ineligibility with 4 years 16/06/2027 Since 03.03.19 No Doping (Testesterone) and Participation During (3000m+) Participation During Ineligibility ITA ineligibility added to the Ineligibility In competition test, Finale Coupe du Trone, Sidi Kacem, BARID, Idriss 12/12/1986 MAR athlete M Hammer Throws 30/06/2019 4 years ineligibility 01/08/2023 Since 30.06.19 No Doping Presence,Use Stanozolol MAR Long Distance Use or Attempted Use by an Athlete of a Prohibited BARTSAYKIN, Alexey 22/03/1989 RUS athlete M Race Walk 01/01/2012 4 years ineligibility 03/07/2021 From 09.09.12 No Doping Use Athlete Biological Passport (3000m+) Substance or a Prohibited Method 4 years ineligibility with 8 Long Distance Presence,Use,Violation of the Prohibition of Norandrosterone, Exogenous Steroids, EPO and In competition
Recommended publications
  • Effects of Androgenic-Anabolic Steroids on Apolipoproteins and Lipoprotein (A) F Hartgens, G Rietjens, H a Keizer, H Kuipers, B H R Wolffenbuttel

    Effects of Androgenic-Anabolic Steroids on Apolipoproteins and Lipoprotein (A) F Hartgens, G Rietjens, H a Keizer, H Kuipers, B H R Wolffenbuttel

    253 Br J Sports Med: first published as 10.1136/bjsm.2003.000199 on 21 May 2004. Downloaded from ORIGINAL ARTICLE Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a) F Hartgens, G Rietjens, H A Keizer, H Kuipers, B H R Wolffenbuttel ............................................................................................................................... Br J Sports Med 2004;38:253–259. doi: 10.1136/bjsm.2003.000199 Objectives: To investigate the effects of two different regimens of androgenic-anabolic steroid (AAS) administration on serum lipid and lipoproteins, and recovery of these variables after drug cessation, as indicators of the risk for cardiovascular disease in healthy male strength athletes. Methods: In a non-blinded study (study 1) serum lipoproteins and lipids were assessed in 19 subjects who self administered AASs for eight or 14 weeks, and in 16 non-using volunteers. In a randomised double blind, placebo controlled design, the effects of intramuscular administration of nandrolone decanoate (200 mg/week) for eight weeks on the same variables in 16 bodybuilders were studied (study 2). Fasting serum concentrations of total cholesterol, triglycerides, HDL-cholesterol (HDL-C), HDL2-cholesterol (HDL2- C), HDL3-cholesterol (HDL3-C), apolipoprotein A1 (Apo-A1), apolipoprotein B (Apo-B), and lipoprotein (a) (Lp(a)) were determined. Results: In study 1 AAS administration led to decreases in serum concentrations of HDL-C (from 1.08 (0.30) to 0.43 (0.22) mmol/l), HDL2-C (from 0.21 (0.18) to 0.05 (0.03) mmol/l), HDL3-C (from 0.87 (0.24) to 0.40 (0.20) mmol/l, and Apo-A1 (from 1.41 (0.27) to 0.71 (0.34) g/l), whereas Apo-B increased from 0.96 (0.13) to 1.32 (0.28) g/l.
  • 2013 House Judiciary Hb 1070

    2013 House Judiciary Hb 1070

    2013 HOUSE JUDICIARY HB 1070 2013 HOUSE STANDING COMMITTEE MINUTES House Judiciary Committee Prairie Room, State Capitol HB 1070 January 14, 2013 Job #17167 D Conference Committee � · Committee Clerk Signature A-. .;' /) .1� ' I A.J4-��'N'f?4<'71<P2/ I Explanation or reason for introduction of bill/resolution: Relating to the scheduling of controlled substances. Minutes: Chairman Koppelman: Opened the hearing on HB 1070. Mark Hardy, Assistant Executive Director of the NO State Board of Pharmacy: (See testimony #1and 2) He went over these handouts. Rep. Klemin: I don't see an emergency clause in the bill and there is none in the amendment. Did I miss it? Mark Hardy: I want to put an emergency clause on the bill. Rep. Klemin: I think you have to have another section at the end of the bill saying this is an emergency. Rep. Kretschmar: How often do these new drugs come out and should be on it? Mark Hardy: As far as the schedule 1 substances; it is a revolving door and we are always trying to stay in front of what the chemists and what the drug makers are doing. As far as schedule 2 through 5; it is a continuous thing through the DEA. When it becomes a federally controlled substance it takes precedence. Rep. Larson: You have not been aware of the bill I was sponsoring regarding synthetic drugs yet? Mark Hardy: No. The Attorney General briefed me on the Bill #1133. Rep. Larson: The reason for my bill is not get into all of the pharmaceutical names of the chemicals, but anybody that possess or manufacturers a analog in order to try and copy these drugs would be guilty of those offences without having to know the specific chemical compound that might be morphed by unscrupulous people trying to see these products.
  • ASIAN Athletics 2 0 1 7 R a N K I N G S

    ASIAN Athletics 2 0 1 7 R a N K I N G S

    ASIAN athletics 2 0 1 7 R a n k i n g s compiled by: Heinrich Hubbeling - ASIAN AA Statistician – C o n t e n t s Page 1 Table of Contents/Abbreviations for countries 2 - 3 Introduction/Details 4 - 9 Asian Continental Records 10 - 60 2017 Rankings – Men events 60 Name changes (to Women´s Rankings) 61 - 108 2017 Rankings – Women events 109 – 111 Asian athletes in 2017 World lists 112 Additions/Corrections to 2016 Rankings 113 - 114 Contacts for other publications etc. ============================================================== Abbreviations for countries (as used in this booklet) AFG - Afghanistan KGZ - Kyrghizstan PLE - Palestine BAN - Bangladesh KOR - Korea (South) PRK - D P R Korea BHU - Bhutan KSA - Saudi Arabia QAT - Qatar BRN - Bahrain KUW - Kuwait SGP - Singapore BRU - Brunei LAO - Laos SRI - Sri Lanka CAM - Cambodia LBN - Lebanon SYR - Syria CHN - China MAC - Macau THA - Thailand HKG - Hongkong MAS - Malaysia TJK - Tajikistan INA - Indonesia MDV - Maldives TKM - Turkmenistan IND - India MGL - Mongolia TLS - East Timor IRI - Iran MYA - Myanmar TPE - Chinese Taipei IRQ - Iraq NEP - Nepal UAE - United Arab E. JOR - Jordan OMA - Oman UZB - Uzbekistan JPN - Japan PAK - Pakistan VIE - Vietnam KAZ - Kazakhstan PHI - Philippines YEM - Yemen ============================================================== Cover Photo: MUTAZ ESSA BARSHIM -World Athlet of the Year 2017 -World Champion 2017 -World 2017 leader with 2.40 m (achieved twice) -undefeated during the 2017 season 1 I n t r o d u c t i o n With this booklet I present my 29th consecutive edition of Asian athletics statistics. As in the previous years I am very grateful to the ASIAN ATHLETICS ASSOCIATION and its secretary and treasurer, Mr Maurice Nicholas as well as to Mrs Regina Long; without their support I would not have been able to realise this project.
  • Us Anti-Doping Agency

    Us Anti-Doping Agency

    2019U.S. ANTI-DOPING AGENCY WALLET CARDEXAMPLES OF PROHIBITED AND PERMITTED SUBSTANCES AND METHODS Effective Jan. 1 – Dec. 31, 2019 CATEGORIES OF SUBSTANCES PROHIBITED AT ALL TIMES (IN AND OUT-OF-COMPETITION) • Non-Approved Substances: investigational drugs and pharmaceuticals with no approval by a governmental regulatory health authority for human therapeutic use. • Anabolic Agents: androstenediol, androstenedione, bolasterone, boldenone, clenbuterol, danazol, desoxymethyltestosterone (madol), dehydrochlormethyltestosterone (DHCMT), Prasterone (dehydroepiandrosterone, DHEA , Intrarosa) and its prohormones, drostanolone, epitestosterone, methasterone, methyl-1-testosterone, methyltestosterone (Covaryx, EEMT, Est Estrogens-methyltest DS, Methitest), nandrolone, oxandrolone, prostanozol, Selective Androgen Receptor Modulators (enobosarm, (ostarine, MK-2866), andarine, LGD-4033, RAD-140). stanozolol, testosterone and its metabolites or isomers (Androgel), THG, tibolone, trenbolone, zeranol, zilpaterol, and similar substances. • Beta-2 Agonists: All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Most inhaled beta-2 agonists are prohibited, including arformoterol (Brovana), fenoterol, higenamine (norcoclaurine, Tinospora crispa), indacaterol (Arcapta), levalbuterol (Xopenex), metaproternol (Alupent), orciprenaline, olodaterol (Striverdi), pirbuterol (Maxair), terbutaline (Brethaire), vilanterol (Breo). The only exceptions are albuterol, formoterol, and salmeterol by a metered-dose inhaler when used
  • Annual Report 2016

    Annual Report 2016

    ANNUAL REPORT 2016 Facts and Introduction Corporate Manufacturing Products Markets Personnel Communication Figures speech Governance Policy Policy CONTENTS Facts and Figures Introduction speech by the Chairmen of the Council and Board Corporate Governance Manufacturing Products Markets Personnel Policy Communication Policy “Grindeks” Group – JSC “Grindeks” and five its subsidiary companies – JSC “Tallin Pharmaceutical plant” in Estonia, JSC “Kalceks” in Latvia, “Namu Apsaimniekošanas projekti” Ltd in Latvia, “Grindeks Rus” Ltd in Russia and “HBM Pharma” Ltd in Slovakia Core business – research, development, manufacturing and sales of original products, generics and active pharmaceutical ingredients Turnover – 105.4 million euros Net profit – 9.5 million euros Investments – 5.5 million euros Gross profit margin – 55% Net profit margin – 9% Export volume – 95.7 million euros Export countries – 71 Main markets – European Union, Russia and other CIS countries, USA, Canada, Japan and Vietnam FACTS AND FIGURES OF 2016 ANNUAL REPORT 2016 SALES OF FINAL DOSAGE FORMS Final dosage forms sales volume – 97.5 million euros Sales volume in Russia, other CIS countries and Georgia – 58.2 million euros Sales volume in the Baltic States and other countries – 39.3 million euros TOP products – meldonium, tegafurum, zopiclone, risperidone, ipidacrine, oxytocin, pain relief ointments and dietary supplementsApilak-Grindeks. SALES OF ACTIVE PHARMACEUTICAL INGREDIENTS (API'S) Sales volume of API's – 6.3 million euros Offered 17 API's The most demanded API's of “Grindeks” – oxytocin, zopiclone, droperidol, detomidine, and pimobendan. QUALITY AND ENVIRONMENTAL CONTROL “Good Manufacturing Practice” certificates for manufacturing of final dosage forms and active pharmaceutical ingredients ISO 9001; ISO 14001; LVS OHSAS 18001 certificates Russian ГОСТ ISO 9001-2011 certificate LVS EN ISO 50001:2012 Energy management certificate FACTS AND FIGURES OF 2016 ANNUAL REPORT 2016 achievements, the greater our ability to invest in further business growth.
  • CAS Number Index

    CAS Number Index

    2334 CAS Number Index CAS # Page Name CAS # Page Name CAS # Page Name 50-00-0 905 Formaldehyde 56-81-5 967 Glycerol 61-90-5 1135 Leucine 50-02-2 596 Dexamethasone 56-85-9 963 Glutamine 62-44-2 1640 Phenacetin 50-06-6 1654 Phenobarbital 57-00-1 514 Creatine 62-46-4 1166 α-Lipoic acid 50-11-3 1288 Metharbital 57-22-7 2229 Vincristine 62-53-3 131 Aniline 50-12-4 1245 Mephenytoin 57-24-9 1950 Strychnine 62-73-7 626 Dichlorvos 50-23-7 1017 Hydrocortisone 57-27-2 1428 Morphine 63-05-8 127 Androstenedione 50-24-8 1739 Prednisolone 57-41-0 1672 Phenytoin 63-25-2 335 Carbaryl 50-29-3 569 DDT 57-42-1 1239 Meperidine 63-75-2 142 Arecoline 50-33-9 1666 Phenylbutazone 57-43-2 108 Amobarbital 64-04-0 1648 Phenethylamine 50-34-0 1770 Propantheline bromide 57-44-3 191 Barbital 64-13-1 1308 p-Methoxyamphetamine 50-35-1 2054 Thalidomide 57-47-6 1683 Physostigmine 64-17-5 784 Ethanol 50-36-2 497 Cocaine 57-53-4 1249 Meprobamate 64-18-6 909 Formic acid 50-37-3 1197 Lysergic acid diethylamide 57-55-6 1782 Propylene glycol 64-77-7 2104 Tolbutamide 50-44-2 1253 6-Mercaptopurine 57-66-9 1751 Probenecid 64-86-8 506 Colchicine 50-47-5 589 Desipramine 57-74-9 398 Chlordane 65-23-6 1802 Pyridoxine 50-48-6 103 Amitriptyline 57-92-1 1947 Streptomycin 65-29-2 931 Gallamine 50-49-7 1053 Imipramine 57-94-3 2179 Tubocurarine chloride 65-45-2 1888 Salicylamide 50-52-2 2071 Thioridazine 57-96-5 1966 Sulfinpyrazone 65-49-6 98 p-Aminosalicylic acid 50-53-3 426 Chlorpromazine 58-00-4 138 Apomorphine 66-76-2 632 Dicumarol 50-55-5 1841 Reserpine 58-05-9 1136 Leucovorin 66-79-5
  • Maciej Łuczak Oszustwo Dopingowe W Sporcie Wyczynowym

    Maciej Łuczak Oszustwo Dopingowe W Sporcie Wyczynowym

    ROZPRAWY NAUKOWE Akademii Wychowania Fizycznego we Wrocławiu 2018, 60, 118 – 134 Maciej Łuczak Akademia Wychowania Fizycznego w Poznaniu OSZUSTWO DOPINGOWE W SPORCIE WYCZYNOWYM WśRÓD KOBIET W LATACH 1950–2017 Cel badań. W artykule przedstawiono zjawisko dopingu kobiet w sporcie w XX i XXI w. Wśród sportsmenek sztuczne wspomaganie wykryto w latach 50. XX w. W niektórych krajach powstał system maskowania dopingu przez władze państwowe. Doświadczenie w zakresie opracowywania i podawania leków wspomagających miały laboratoria antydopingowe, m.in. w Kreischa w NRD. Stosowanie niedozwolonych praktyk ukazano na przykładzie NRD, RFN, ZSRR, Chin, USA, Kenii i Polski. Materiał i metody. Materiał badawczy został zinterpretowany przy użyciu metod stoso- wanych w naukach historycznych: indukcyjnej, dedukcyjnej, komparatystycznej i analizy litera- tury specjalistycznej. Do sformułowania ostatecznych wniosków wykorzystano metodę syntezy. Wyniki. Praktyki dopingowe miały miejsce w wielu krajach. Od 1956 r. notuje się stosowanie wspomagania organizmów sportsmenek za pomocą testosteronu. Z czasem doszły bardziej udo- skonalone niedozwolone środki oraz metody, takie jak np. doping ciążowy. Najbardziej zorganizo- wany doping pod kuratelą państwa miał miejsce w NRD, RFN, ZSRR, Chinach, USA, Kenii i w Polsce. Wnioski. W latach 50. XX w. zawodniczki – zwłaszcza w Związku Radzieckim – spo- radycznie przyjmowały testosteron oraz steroidy anaboliczno-androgenne. Później liczba stoso- wanych środków dopingujących systematycznie rosła. Na większą skalę zaczęto je przyjmować dopiero w latach 70. i 80. XX w. Próbą zapanowania nad tym zjawiskiem są badania antydopin- gowe, jednak chęć zwycięstwa często przeważa nad zdrowym rozsądkiem. Słowa kluczowe: sport, doping, historia, kobiety WprowadzEniE Doping w sporcie znany jest od bardzo dawna. Zapewne byłby łatwiejszy do wykrycia, gdyby nie korzyści płynące z niego dla firm farmaceutycznych, lekarzy, trenerów, za- wodników, federacji sportowych oraz polityków i rządów państw.
  • MMC International BV

    MMC International BV

    M.M.C. International Steroid Substances Steroid Test A Colour Steroid Test B Colour Steroid Test B Colour with UV Light Stanozolol/ Oxandrolone Test Clenbuterol/ Oxymetholone Test Ephedrine Test Alfadolone Orange Yellow Nil - - - Androsterone Orange Yellow White - - - Beclometasone Brown–yellow Orange Nil - - - Betamethasone Orange–brown Pink–Orange Nil - - - Boldenone Base (Equipoise, Ganabol) (pure powder) Warm red after 2 min. Dark Orange after 2 min. Bright Light Orange - - - Boldenone Undecanoate (oil) Dark brownish-red Dark Red Bright Light Orange - - - Boldenone Undecylenate (oil) Orange - Light Brown Dark Orange → Brown Bright Light Orange-Yellow - - - Carbenoxolone (CBX) Orange Yellow Yellow - - - Cholesterol Violet Orange White - - - Clenbuterol (Spiropent, Ventipulmin) - - - - Purple - Dark brown with yellow-green on the Dark brown with yellow-green on the Clomiphene (Androxal, Clomid, Omifin) Nil Dark brown to black No reaction Dark brown to black sides of the ampoule sides of the ampoule Cortisone Orange Yellow Green - - - Desoxycortone Blue–black Yellow Yellow - - - Dexamethasone Yellow Orange–pink Nil - - - Dienestrol Yellow Orange–red Nil - - - Diethylstilbestrol (DES) Orange (→yellow–green) Nil - - - Dimethisterone Brown–green Orange–red Yellow - - - Drostanolone Propionate (Masteron) (oil) Bright green Yellow-Orange Orange - - - Dydrogesterone (Duphaston) - Orange Green-Yellow - - - Enoxolone Orange Yellow Green-Yellow - - - Ephedrine (also for Pseudo- and Nor-Ephedrine) - - - - - Orange Estradiol (Oestradiol) Orange
  • 2017 Anti-Doping Testing Figures Report

    2017 Anti-Doping Testing Figures Report

    2017 Anti‐Doping Testing Figures Please click on the sub‐report title to access it directly. To print, please insert the pages indicated below. Executive Summary – pp. 2‐9 (7 pages) Laboratory Report – pp. 10‐36 (26 pages) Sport Report – pp. 37‐158 (121 pages) Testing Authority Report – pp. 159‐298 (139 pages) ABP Report‐Blood Analysis – pp. 299‐336 (37 pages) ____________________________________________________________________________________ 2017 Anti‐Doping Testing Figures Executive Summary ____________________________________________________________________________________ 2017 Anti-Doping Testing Figures Samples Analyzed and Reported by Accredited Laboratories in ADAMS EXECUTIVE SUMMARY This Executive Summary is intended to assist stakeholders in navigating the data outlined within the 2017 Anti -Doping Testing Figures Report (2017 Report) and to highlight overall trends. The 2017 Report summarizes the results of all the samples WADA-accredited laboratories analyzed and reported into WADA’s Anti-Doping Administration and Management System (ADAMS) in 2017. This is the third set of global testing results since the revised World Anti-Doping Code (Code) came into effect in January 2015. The 2017 Report – which includes this Executive Summary and sub-reports by Laboratory , Sport, Testing Authority (TA) and Athlete Biological Passport (ABP) Blood Analysis – includes in- and out-of-competition urine samples; blood and ABP blood data; and, the resulting Adverse Analytical Findings (AAFs) and Atypical Findings (ATFs). REPORT HIGHLIGHTS • A analyzed: 300,565 in 2016 to 322,050 in 2017. 7.1 % increase in the overall number of samples • A de crease in the number of AAFs: 1.60% in 2016 (4,822 AAFs from 300,565 samples) to 1.43% in 2017 (4,596 AAFs from 322,050 samples).
  • 207/2015 3 Lääkeluettelon Aineet, Liite 1. Ämnena I Läkemedelsförteckningen, Bilaga 1

    207/2015 3 Lääkeluettelon Aineet, Liite 1. Ämnena I Läkemedelsförteckningen, Bilaga 1

    207/2015 3 LÄÄKELUETTELON AINEET, LIITE 1. ÄMNENA I LÄKEMEDELSFÖRTECKNINGEN, BILAGA 1. Latinankielinen nimi, Suomenkielinen nimi, Ruotsinkielinen nimi, Englanninkielinen nimi, Latinskt namn Finskt namn Svenskt namn Engelskt namn (N)-Hydroxy- (N)-Hydroksietyyli- (N)-Hydroxietyl- (N)-Hydroxyethyl- aethylprometazinum prometatsiini prometazin promethazine 2,4-Dichlorbenzyl- 2,4-Diklooribentsyyli- 2,4-Diklorbensylalkohol 2,4-Dichlorobenzyl alcoholum alkoholi alcohol 2-Isopropoxyphenyl-N- 2-Isopropoksifenyyli-N- 2-Isopropoxifenyl-N- 2-Isopropoxyphenyl-N- methylcarbamas metyylikarbamaatti metylkarbamat methylcarbamate 4-Dimethyl- ami- 4-Dimetyyliaminofenoli 4-Dimetylaminofenol 4-Dimethylaminophenol nophenolum Abacavirum Abakaviiri Abakavir Abacavir Abarelixum Abareliksi Abarelix Abarelix Abataceptum Abatasepti Abatacept Abatacept Abciximabum Absiksimabi Absiximab Abciximab Abirateronum Abirateroni Abirateron Abiraterone Acamprosatum Akamprosaatti Acamprosat Acamprosate Acarbosum Akarboosi Akarbos Acarbose Acebutololum Asebutololi Acebutolol Acebutolol Aceclofenacum Aseklofenaakki Aceklofenak Aceclofenac Acediasulfonum natricum Asediasulfoni natrium Acediasulfon natrium Acediasulfone sodium Acenocoumarolum Asenokumaroli Acenokumarol Acenocumarol Acepromazinum Asepromatsiini Acepromazin Acepromazine Acetarsolum Asetarsoli Acetarsol Acetarsol Acetazolamidum Asetatsoliamidi Acetazolamid Acetazolamide Acetohexamidum Asetoheksamidi Acetohexamid Acetohexamide Acetophenazinum Asetofenatsiini Acetofenazin Acetophenazine Acetphenolisatinum Asetofenoli-isatiini
  • Rapport 2008

    Rapport 2008

    rapport 2008 Reseptregisteret 2004-2007 The Norwegian Prescription Database 2004-2007 Marit Rønning Christian Lie Berg Kari Furu Irene Litleskare Solveig Sakshaug Hanne Strøm Rapport 2008 Nasjonalt folkehelseinstitutt/ The Norwegian Institute of Public Health Tittel/Title: Reseptregisteret 2004-2007 The Norwegian Prescription Database 2004-2007 Redaktør/Editor: Marit Rønning Forfattere/Authors: Christian Lie Berg Kari Furu Irene Litleskare Marit Rønning Solveig Sakshaug Hanne Strøm Publisert av/Published by: Nasjonalt folkehelseinstitutt Postboks 4404 Nydalen NO-0403 Norway Tel: + 47 21 07 70 00 E-mail: [email protected] www.fhi.no Design: Per Kristian Svendsen Layout: Grete Søimer Acknowledgement: Julie D.W. Johansen (English version) Forsideillustrasjon/Front page illustration: Colourbox.com Trykk/Print: Nordberg Trykk AS Opplag/ Number printed: 1200 Bestilling/Order: [email protected] Fax: +47-21 07 81 05 Tel: +47-21 07 82 00 ISSN: 0332-6535 ISBN: 978-82-8082-252-9 trykt utgave/printed version ISBN: 978-82-8082-253-6 elektronisk utgave/electronic version 2 Rapport 2008 • Folkehelseinstituttet Forord Bruken av legemidler i befolkningen er økende. En viktig målsetting for norsk legemiddelpolitikk er rasjonell legemiddelbruk. En forutsetning for arbeidet med å optimalisere legemiddelbruken i befolkningen er kunnskap om hvilke legemidler som brukes, hvem som bruker legemidlene og hvordan de brukes. For å få bedre kunnskap på dette området, vedtok Stortinget i desember 2002 å etablere et nasjonalt reseptbasert legemiddelregister (Reseptregisteret). Oppgaven med å etablere registeret ble gitt til Folkehelseinstituttet som fra 1. januar 2004 har mottatt månedlige opplysninger fra alle apotek om utlevering av legemidler til pasienter, leger og institusjoner. Denne rapporten er første utgave i en planlagt årlig statistikk fra Reseptregisteret.
  • 17Th ASIAN GAMES at Incheon/KOR, 27.09. – 03.10.2014

    17Th ASIAN GAMES at Incheon/KOR, 27.09. – 03.10.2014

    17th ASIAN GAMES at Incheon/KOR, 27.09. – 03.10.2014 -following are the complete results plus detailed additional information (medal & placing table, updated ASIAN GAMES Records etc.) from the Athletics competitions at the ASIAN GAMES- -with thanks to Mr Mirko Jalava and information from his excellent TILASTOPAJA-website – -athletes from 42 (out of the 45) ASIAN AA Member Federations participated (i.e. all except BAN, BRU & JOR) – the following statistical details are a proof for the outstanding standards in most events at these Games: -a comparison of the results for the winners to the Gold medalists from Guangzhou (2010 Games) shows better performances in 37 events (13 by Men & 14 by Women) against better performances at the 2010 Games in the other 19 events (10 by Men & 9 by Women); the remaining (47th) event, Men´s 50 km Walk, was not held 4 years ago; in addition another better time (one of the new GR´s) compared to the 2010 Games was achieved in a heat of Women´s 400 m hurdles – -see additional remarks concerning the outstanding standards at these Games on pages 28 & 29 - -the following abbreviations are used in the results section below (number of new records achieved in each category shown in bracketts); records broken twice (i.e. in a heat and again improved in a final) are not even counted for this survey: -AR = new Area Records (= 3); GR = new Games Records (= 18 – including 1 equalled GR) -NR = new National Records (= 44); these NR´s were achieved by athletes from 26 different federations with the most new records (each in